1:10 Stock Split: Chemicals Stock Set To Get Affordable, Shares Soar 407% In 3-Months

Small cap company engaged in specialty chemicals industry, Sudarshan Pharma Industries shares today declined 1.49% to settle at Rs 412.35 per share. The Board of Directors of Sudarshan Pharma Industries today approved 1:10 stock split implying 1 share will be split/sub-divided into 10 new shares as on the record date. Sudarshan Pharma Industries shares delivered shareholders return of 123% in last 1-month and gained 407% in last 3-months. The company's market capitalization stood at Rs 992.36 crore. Check the key details below:

Sudarshan Pharma Industries Approves Stock Split: As per the exchange filing of Sudarshan Pharma Industries dated September 30, 2024, "sub-division / split of company's 1 (one) equity share having face value of Rs.10/- (Rupees Ten only) each fully paid-up, into 10 (Ten) equity shares of the Company having face value of Re.1/- (Rupee One only) each fully paid-up, subject to the approval of shareholders and such other approvals as may be required."

Sudarshan Pharma Shares Performance: The 52-week high price of Sudarshan Pharma Industries shares on BSE is Rs 434.00 per share (as on 26/09/2024) and 52-week low price is Rs 58.20 per share (as on 04/06/2024), respectively. Sudarshan Pharma Industries shares offered gain of 124% in last 1-month, rallied 456% in last 6-months, and rose 390% in last 1-year.

Sudarshan Pharma Industries About: Originally incorporated as 'Sudarshan Specialty Chemsolve Private Limited' in 2008 in Mumbai, it was subsequently named 'Sudarshan Pharma Industries Private Limited'. In 2016 the company was listed as a public limited company and became 'Sudarshan Pharma Industries Limited' (SPIL). The Company's promoters, Mr Hemal V Mehta & Mr Sachin V Mehta have a combined experience of over 25 years in the Special Chemical, Bulk drug and Pharmaceutical Industry, according to its official website.

Disclaimer: The stock highlights the stock split and is not a recommendation to buy, sell or hold. We have not done fundamental or technical analysis and have no opinion on the stock mentioned. Neither, the author nor Greynium Information Technologies should be held liable for any losses. Please consult a professional advisor.